Abstract
Background
Controversy exists on the impact of bilaterality of breast cancer on survival. We used population-based data to compare survival of women with unilateral versus bilateral breast cancer.
Patients and methods
At the Geneva cancer registry, we identified all 7,912 women diagnosed with invasive breast cancer between 1970 and 2002. Breast cancers were categorized as unilateral, synchronous bilateral (contralateral tumour diagnosed within six months after the first tumour) and metachronous bilateral (contralateral tumour diagnosed over six months after the first tumour). With multivariate modelling we compared characteristics and survival between women with unilateral and bilateral disease.
Results
Patients with synchronous bilateral tumours (n = 155, 2.0%) had more often lobular histology and less frequently stage I disease than women with unilateral disease. Women with metachronous breast cancer (n = 219, 2.8%) received less often chemotherapy or hormone therapy for their first tumours. Ten-year disease-specific survival was similar (66%) after unilateral and metachronous bilateral breast cancer, but worse after synchronous bilateral cancer (51%). After adjustment, breast cancer mortality risks were not significantly increased for women with either synchronous or metachronous bilateral disease (Hazard ratios 1.1 (0.8–1.5) and 0.8 (0.5–1.4), respectively).
Conclusion
This large population-based study indicates that bilaterality of breast cancer is not associated with impaired survival.
Similar content being viewed by others
References
Dawson LA, Chow E, Goss PE (1998) Evolving perspectives in contralateral breast cancer. Eur J Cancer 34:2000–2009
Vaittinen P, Hemminki K (2000) Risk factors and age-incidence relationships for contralateral breast cancer. Int J Cancer 88:998–1002
Carmichael AR, Bendall S, Lockerbie L et al (2002) The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 28:388–391
Newman LA, Sahin AA, Cunningham JE et al (2001) A case-control study of unilateral and bilateral breast carcinoma patients. Cancer 91:1845–1853
Gajalakshmi CK, Shanta V, Hakama M (1999) Survival from contralateral breast cancer. Breast Cancer Res Treat 58:115–122
Anderson DE, Badzioch MD (1985) Bilaterality in familial breast cancer patients. Cancer 56:2092–2098
Hemminki K, Vaittinen P (1999) Familial risks in second primary breast cancer based on a family cancer database. Eur J Cancer 35:455–458
Hartman M, Czene K, Reilly M (2005) Genetic implications of bilateral breast cancer: a population based cohort study. Lancet Oncol 6:377–382
Imyanitov EN, Hanson KP (2003) Molecular pathogenesis of bilateral breast cancer. Cancer Lett 191:1–7
Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477
Chappuis PO, Stoppa-Lyonnet D, Asselain B et al (2002) The natural history of hereditary breast cancer. In: Morrison PJ, Hodgson SV, Haites NE (eds) Familial breast and ovarian cancer. Cambridge University Press, Cambridge
Steinmann D, Bremer M, Rades D et al (2001) Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. Br J Cancer 85:850–858
Holmberg L, Adami HO, Ekbom A et al (1988) Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. Br J Cancer 58:191–194
Wanebo HJ, Senofsky GM, Fechner RE et al (1985) Bilateral breast cancer. Risk reduction by contralateral biopsy. Ann Surg 201:667–677
Levi F, Randimbison L, Te VC et al (2003) Prognosis of bilateral synchronous breast cancer in Vaud, Switzerland. Breast 12:89–91
Kollias J, Ellis IO, Elston CW et al (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25:584–589
Jobsen JJ, van der PJ, Ong F et al (2003) Synchronous, bilateral breast cancer: prognostic value and incidence. Breast 12:83–88
Polednak AP (2003) Bilateral synchronous breast cancer: a population-based study of characteristics, method of detection, and survival. Surgery 133:383–389
Heron DE, Komarnicky LT, Hyslop T et al (2000) Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer 88:2739–2750
Abdalla I, Thisted RA, Heimann R (2000) The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. Cancer J 6:266–272
Mose S, Adamietz IA, Thilmann C et al (1997) Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 20:541–545
Bouchardy C (1997) Switzerland Geneva. In: Parkin DM, Whelan SL, Ferlay J et al (eds) Cancer incidence in five continents, vol VII. International Agency for Research on Cancer, Lyon
ICD-O International classification of diseases for oncology (1976) 1st edn. World Health Organization, Geneva
TNM classification of malignant tumours (2002) 6th edn. UICC, New York
Intra M, Rotmensz N, Viale G et al (2004) Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 101:905–912
Mertens WC, Hilbert V, Makari-Judson G (2004) Contralateral breast cancer: factors associated with stage and size at presentation. Breast J 10:304–312
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Gajalakshmi CK, Shanta V, Hakama M (1998) Risk factors for contralateral breast cancer in Chennai (Madras), India. Int J Epidemiol 27:743–750
Verkooijen HM, Fioretta G, Chappuis PO et al (2004) Set-up of a population-based familial breast cancer registry in Geneva, Switzerland: validation of first results. Ann Oncol 15:350–353
Gershoni-Baruch R, Dagan E, Fried G et al (1999) BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J Hum Genet 7:833–836
Nelson HD, Huffman LH, Fu R et al (2005) Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 143:362–379
Hampel H, Sweet K, Westman JA et al (2004) Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 41:81–91
Kollias J, Ellis IO, Elston CW et al (2001) Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg 25:1117–1124
Takahashi H, Watanabe K, Takahashi M et al (2005) The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast Cancer 12:196–202
Healey EA, Cook EF, Orav EJ et al (1993) Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol 11:1545–1552
Acknowledgement
Helena M. Verkooijen was supported by PROSPER Grant (323-3069350) from the Swiss National Science Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Verkooijen, H.M., Chatelain, V., Fioretta, G. et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105, 347–357 (2007). https://doi.org/10.1007/s10549-006-9455-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9455-x